ketanserin has been researched along with Tourette Syndrome in 3 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Tourette Syndrome: A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty adults with Tourette's syndrome and 20 healthy control subjects were investigated with PET-[18F]altanserin using a bolus-infusion protocol." | 1.34 | Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. ( Bolwig, TG; Hansen, ES; Haugbøl, S; Knudsen, GM; Nielsen, FA; Pinborg, LH; Regeur, L; Skovgaard, LT; Svarer, C, 2007) |
| " Initially, we established a dose-response relationship for the acute and chronic haloperidol and DOI-induced HTR." | 1.33 | Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome. ( Hayslett, RL; Tizabi, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayslett, RL | 1 |
| Tizabi, Y | 1 |
| Haugbøl, S | 1 |
| Pinborg, LH | 1 |
| Regeur, L | 1 |
| Hansen, ES | 1 |
| Bolwig, TG | 1 |
| Nielsen, FA | 1 |
| Svarer, C | 1 |
| Skovgaard, LT | 1 |
| Knudsen, GM | 1 |
| Bonnier, C | 1 |
| Nassogne, MC | 1 |
| Evrard, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome[NCT04794413] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-11-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ketanserin and Tourette Syndrome
| Article | Year |
|---|---|
Ketanserin treatment of Tourette's syndrome in children.
Topics: Adolescent; Age Factors; Child; Drug Administration Schedule; Female; Humans; Ketanserin; Male; Sero | 1999 |
2 other studies available for ketanserin and Tourette Syndrome
| Article | Year |
|---|---|
Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome.
Topics: Amphetamines; Animals; Behavior, Animal; Binding, Competitive; Cerebral Cortex; Corpus Striatum; Don | 2005 |
Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome.
Topics: Adolescent; Adult; Brain Chemistry; Female; Humans; Ketanserin; Magnetic Resonance Imaging; Male; Mi | 2007 |